Ironwood Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Ironwood Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials none currently recruiting 20 completed early-phase tilt top decile by trial count

Ironwood Pharmaceuticals: 23 sponsored US clinical trials, none currently recruiting.

Ironwood Pharmaceuticals sponsors 23 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 20 completed. 8 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Constipation, with 1 trials.

Top-decile sponsor footprint

Ironwood Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 57/100

20 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

23 total, page 1 of 1

TERMINATED Phase 2

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT05740007
COMPLETED Phase 1

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

NCT05362695
COMPLETED Phase 1

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

NCT05188261
COMPLETED Phase 2

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

NCT03931785
COMPLETED Phase 1

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
COMPLETED Phase 3

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

NCT03561883
COMPLETED Phase 3

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03573908
TERMINATED Phase 3

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

NCT03561090
TERMINATED Phase 4

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
COMPLETED Phase 2

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
COMPLETED Phase 2

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02559206
COMPLETED Phase 2

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

NCT02289846
COMPLETED Phase 3

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

NCT02291679
COMPLETED Phase 2

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

NCT02030925
COMPLETED Phase 2

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

NCT01107236
COMPLETED Phase 3

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00938717
COMPLETED Phase 3

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00730171
COMPLETED Phase 3

Trial of Linaclotide in Patients With Chronic Constipation

NCT00730015
COMPLETED Phase 2

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
COMPLETED Phase 2

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

NCT00404001
COMPLETED Phase 2

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

NCT00402337
COMPLETED Phase 2

Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation

NCT00306748
COMPLETED Phase 2

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

NCT00258193

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 12
Phase 3 7
Phase 4 1

Therapeutic Areas

Chronic Constipation 1
Hypercholesterolemia 1
Gastroesophageal Reflux Disease 1
Healthy Volunteers 1
Healthy 1

How the Ironwood Pharmaceuticals early-phase archive is shaped

23 indexed studies, none listed as recruiting (0% open); 20 completed (87%).

Phase mix: 8 late (III/IV) vs 15 early (I/II) (early-phase heavy).

Top condition: Chronic Constipation (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ironwood Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 23 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ironwood Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20%25% Total trials Recruiting share Ironwood PharmaceuticalsAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, Jr10xBio22nd Century Group23andMe3-C Institute for Social Development
Ironwood Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ironwood Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ironwood Pharmaceuticals page

23 registered trials is a research-attention snapshot, not an endorsement of Ironwood Pharmaceuticals or any single study.

  • None of Ironwood Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Chronic Constipation is the condition Ironwood Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Constipation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ironwood Pharmaceuticals pipeline card: 23 registered trials from official public datasets.Report a data error.